| Date | Title | Description | Source |
| 05.09.2023 | BRIXADI® (buprenorphine) Extended-Release Injection for Subc... | BRIXADI is now available for healthcare settings and pharmacies through a restricted distribution pr... | appletreep... |
| 05.09.2023 | BRIXADI® (buprenorphine) Extended-Release Injection for Subc... | BRIXADI is now available for healthcare settings and pharmacies through a restricted distribution pr... | appletreep... |
| 23.05.2023 | Braeburn's BRIXADI™ (buprenorphine) Extended-Release Subcuta... | BRIXADI is the first and only long-acting buprenorphine injectable with both weekly and monthly dose... | appletreep... |
| 23.05.2023 | Braeburn's BRIXADI™ (buprenorphine) Extended-Release Subcuta... | BRIXADI is the first and only long-acting buprenorphine injectable with both weekly and monthly dose... | appletreep... |
| 23.12.2022 | Braeburn Applauds Passage of Significant Advancements in the... | Plymouth Meeting, Pa.—December 23, 2022—The recently passed Senate Amendment to H.R. 2617 – Consolid... | appletreep... |
| 23.12.2022 | Braeburn Applauds Passage of Significant Advancements in the... | Plymouth Meeting, Pa.—December 23, 2022—The recently passed Senate Amendment to H.R. 2617 – Consolid... | appletreep... |
| 08.12.2022 | FDA Accepts Braeburn’s New Drug Application Resubmission for... | Prescription Drug User Fee Act (PDUFA) action date set for May 23, 2023.
Plymouth Meeting, Pa. – De... | appletreep... |
| 08.12.2022 | FDA Accepts Braeburn’s New Drug Application Resubmission for... | Prescription Drug User Fee Act (PDUFA) action date set for May 23, 2023.
Plymouth Meeting, Pa. – De... | appletreep... |
| 26.06.2021 | FDA Accepts Braeburn’s New Drug Application Resubmission for... | Prescription Drug User Fee Act (PDUFA) action date set for December 15, 2021
Plymouth Meeting, Pa. ... | appletreep... |
| 26.06.2021 | FDA Accepts Braeburn’s New Drug Application Resubmission for... | Prescription Drug User Fee Act (PDUFA) action date set for December 15, 2021
Plymouth Meeting, Pa. ... | appletreep... |
| 26.06.2021 | FDA Accepts Braeburn's New Drug Application Resubmission for... |
PLYMOUTH MEETING, Pa., June 26, 2021 /PRNewswire/ -- Braeburn announces that the New Drug Applicat... | prnewswire... |
| 15.06.2021 | Braeburn Resubmits New Drug Application for BRIXADI™ (bupren... | Plymouth Meeting, Pa. – June 15, 2021 – Braeburn announces that today the New Drug Application (NDA)... | appletreep... |
| 15.06.2021 | Braeburn Resubmits New Drug Application for BRIXADI™ (bupren... |
PLYMOUTH MEETING, Pa., June 15, 2021 /PRNewswire/ -- Braeburn announces that today the New Drug Ap... | prnewswire... |
| 15.06.2021 | Braeburn Resubmits New Drug Application for BRIXADI™ (bupren... | Plymouth Meeting, Pa. – June 15, 2021 – Braeburn announces that today the New Drug Application (NDA)... | avistacap.... |
| 15.06.2021 | Braeburn Resubmits New Drug Application for BRIXADI™ (bupren... | Plymouth Meeting, Pa. – June 15, 2021 – Braeburn announces that today the New Drug Application (NDA)... | appletreep... |
| 10.12.2020 | Braeburn Announces Arbitration Determination that It Did Not... |
PLYMOUTH MEETING, Pa., Dec. 10, 2020 /PRNewswire/ -- Braeburn announces that a tribunal appointed ... | prnewswire... |
| 01.06.2020 | Braeburn Submits Request for Final Approval of BRIXADI™ (bup... | Plymouth Meeting, Pa. — June 1, 2020 — Braeburn announces that it has requested final approval from ... | appletreep... |
| 01.06.2020 | Braeburn Submits Request for Final Approval of BRIXADI™ (bup... | Plymouth Meeting, Pa. — June 1, 2020 — Braeburn announces that it has requested final approval from ... | appletreep... |
| 23.07.2019 | U.S. District Court Orders FDA to Reconsider Application for... | PLYMOUTH MEETING, Pa., July 23, 2019 -- (PRNewswire) -- The U.S. District Court for the District of ... | appletreep... |
| 23.07.2019 | U.S. District Court Orders FDA to Reconsider Application for... | PLYMOUTH MEETING, Pa., July 23, 2019 -- (PRNewswire) -- The U.S. District Court for the District of ... | appletreep... |
| 04.06.2019 | Braeburn Announces Publication of Phase 3 Study Results Show... | PLYMOUTH MEETING, Pa., June 4, 2019 -- (PRNewswire) -- Braeburn Inc. announces the publication of it... | appletreep... |
| 04.06.2019 | Braeburn Announces Publication of Phase 3 Study Results Show... | PLYMOUTH MEETING, Pa., June 4, 2019 -- (PRNewswire) -- Braeburn Inc. announces the publication of it... | appletreep... |
| 11.04.2019 | Braeburn petitions FDA to revoke Sublocade orphan des... | A citizen petition filed last week by law firm Goodwin Procter on behalf of Pennsylvania-b... | endpts.com... |
| 23.12.2018 | Braeburn Announces Tentative FDA Approval of BRIXADI™ (bupre... | BRIXADI™ is a long-acting buprenorphine injectable with both weekly and monthly doses to align with ... | appletreep... |
| 23.12.2018 | Braeburn Announces Tentative FDA Approval of BRIXADI™ (bupre... | BRIXADI™ is a long-acting buprenorphine injectable with both weekly and monthly doses to align with ... | appletreep... |
| 21.09.2018 | CAM2038 Receives Positive CHMP Opinion for the Treatment of ... | Plymouth Meeting, PA—September 21, 2018 — Braeburn announces that Camurus has received a positive op... | appletreep... |
| 21.09.2018 | CAM2038 Receives Positive CHMP Opinion for the Treatment of ... | Plymouth Meeting, PA—September 21, 2018 — Braeburn announces that Camurus has received a positive op... | appletreep... |
| 18.09.2018 | Braeburn Announces Positive Top-line Phase 3 Results for CAM... | Plymouth Meeting, PA—September 18, 2018 — Braeburn announces positive top-line results for a Phase 3... | appletreep... |
| 18.09.2018 | Braeburn Announces Positive Top-line Phase 3 Results for CAM... | Plymouth Meeting, PA—September 18, 2018 — Braeburn announces positive top-line results for a Phase 3... | appletreep... |
| 29.06.2018 | Andrew Ritter gathers the reins as his company preps Ph... | Andrew Ritter
→ The series of executive hiring at Ritter Pharmaceuticals $RTTR has cul... | endpts.com... |
| 10.01.2018 | Braeburn Announces Completion of $110 Million Financing | Princeton, N.J.— January 10, 2018 — Braeburn Pharmaceuticals, Inc. (Braeburn) today announced that t... | avistacap.... |
| - | FDA Grants Braeburn’s Citizen Petition Allowing BRIXADI (bup... | FDA revokes Indivior PLC’s orphan designation for opioid use disorder (OUD)* and prevents an additio... | avistacap.... |
| - | Braeburn Announces PDUFA Date for CAM2038 for the Treatment ... | If approved, CAM2038 will provide patients and HCPs with flexible-dose weekly and monthly options fo... | avistacap.... |
